[online source]
Obese mouse models (Coskun 2022) show basal energy expenditure +8-12% vs vehicle, a major contributor to the magnitude of weight loss observed in phase II clinical trials
But it does mean monitoring is important, especially for patients who already take blood pressure medications, diuretics, heart failure medications, or medications that affect fluid balance
Many patients are turning to telehealth-based programs that prioritize convenience, personalization, and domestic safety
GLP-1 medications are not appropriate for everyone, and the safest plan depends on the patients medical history, current medications, goals, lab markers, and risk factors
Outcomes in obesity Among GLP-1RAs, liraglutide, semaglutide, and tirzepatide are licensed for the treatment of obesity